Tetratherix Limited logo

Tetratherix Limited (TTX)

Market Open
CXA CXA
- Market Cap
- P/E Ratio
- Div Yield
474 Volume
- Eps
Want to track TTX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

TTX is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on ASX (AUD).

Tetratherix Limited (TTX) FAQ

On which exchange is it traded?

Tetratherix Limited is listed on CXA.

What is its stock symbol?

The ticker symbol is TTX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Tetratherix Limited ever had a stock split?

No, there has never been a stock split.

Tetratherix Limited Profile

- Industry
- Sector
Mr. William Anthony Knox CEO
CXA Exchange
AU0000400574 ISIN
Australia Country
15 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Tetratherix Limited is a cutting-edge biomedical company that focuses on the development of advanced biomaterials and regenerative medicine solutions. Since its inception in 2015, the company has been strategically positioned in Alexandria, Australia, at the crossroads of healthcare innovation and advanced material science. Tetratherix's flagship innovation, the Tetramatrix platform, is a proprietary fluid matrix engineered to significantly reduce foreign body reactions, making it exceptionally suitable for a range of sensitive medical applications. The company is dedicated to advancing orthopedic and surgical care through the development and manufacturing of products that facilitate bone regeneration, tissue spacing, and enhanced tissue healing.

With a global operational footprint that extends beyond Australia, Tetratherix is instrumental in pushing the boundaries of medical device technologies by placing a strong emphasis on the creation and utilization of functional biomaterials. The company's diverse activities encompass the entire spectrum of biomedical development—from early-stage research and intellectual property generation to the successful commercialization of innovative medical products. As a result, Tetratherix is recognized as a vital driver of advancement within the biotechnology and medical instruments sectors. Its pioneering solutions are particularly valuable to clinicians aiming to enhance patient outcomes across a variety of regenerative procedures, thereby underscoring its significant impact on healthcare delivery and biomaterial science.

Products and Services

  • Tetramatrix Platform: This proprietary fluid matrix serves as the cornerstone of Tetratherix's innovation, designed to minimize adverse foreign body reactions during medical procedures. Its unique composition makes it ideal for various applications in regenerative medicine, promoting better integration with biological tissues.
  • Bone Regeneration Products: Leveraging the Tetramatrix technology, Tetratherix develops specialized products aimed at facilitating bone healing and regeneration in patients. These solutions are crucial in orthopedic applications, where effective recovery is paramount to successful surgical outcomes.
  • Tissue Spacing Solutions: The company’s offerings include advanced materials that provide optimal spacing for tissues, which is essential for ensuring precise surgical alignments and promoting tissue healing. These solutions are designed to improve the overall efficacy of surgical interventions.
  • Tissue Healing Products: Tetratherix manufactures innovative products aimed at accelerating the healing process of damaged tissues. These offerings incorporate the company’s knowledge in material science to enhance recovery rates and minimize complications in patients undergoing regenerative procedures.
  • Research and Development Services: Beyond its product offerings, Tetratherix engages in active research and development initiatives. This includes collaborative projects with healthcare professionals and institutions to develop novel biomaterials tailored to meet specific clinical needs, ensuring a continuous pipeline of innovation.
  • Commercialization of Medical Products: Tetratherix is committed to taking pioneering ideas from the lab to market. The company's efforts in commercialization help bridge the gap between advanced research and practical applications, broadening access to its innovative solutions in the healthcare sector.

Contact Information

Address: Unit 29
Phone: -